Business Context and Reporting Period
This Form 8-K filing by REGENXBIO Inc. reports on the results of the 2017 annual meeting of stockholders held on May 24, 2017. The company is incorporated in Delaware and identifies as an emerging growth company.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance voting results.
Material Changes
No material financial changes or operational updates are disclosed in this filing. The document serves to disclose the final voting outcomes for the annual meeting.
Guidance, Outlook, and Management Commentary
The filing contains no forward-looking guidance, management commentary on financial performance, or discussion of risks and contingencies. It references the definitive proxy statement filed on April 13, 2017, for further details on the proposals.
Key Facts for Investor Verification
- Director Elections: Three Class II directors were elected to serve until the 2020 annual meeting: Donald J. Hayden, Jr., A.N. "Jerry" Karabelas, Ph.D., and Daniel Tassé.
- Voting Results: Daniel Tassé received the highest number of votes for (22,687,375) and the fewest votes withheld (82,700). Donald J. Hayden, Jr. had the highest votes withheld (2,702,829).
- Broker Non-Votes: There were 2,116,333 broker non-votes for each director election.
- Auditor Ratification: Stockholders ratified the appointment of PricewaterhouseCoopers LLP as the independent registered public accounting firm for the year ending December 31, 2017, with 24,845,246 votes for and only 6,179 votes against.